PMC4427137_01
Clinical appearance before and during therapy with ustekinumab: at baseline (a) and 8 weeks after subcutaneous injection of ustekinumab 90 mg (b).
cde-0007-0046-g01.jpg
PMC4427137_01_cde-0007-0046-g01.jpg
F1
Her rash diminished significantly within 8 weeks (fig. 1) and she reported feeling much less pain.